350 rub
Journal №12 for 2013 г.
Article in number:
Benign prostate hyperplasia models
Keywords: benign prostate hyperplasia testosterone sulpiride prolactin 5α -reductase
Authors:
E.A. Lesovaya - Ph.D. (Biol.), Researcher, Department of Chemical Carcinogenesis, Institute of Carcinogenesis, Blokhin Cancer Research Center RAMS. E-mail: lesovenok@yandex.ru
K.I. Kirsanov - Ph.D. (Biol.), Senior Researcher, Department of Chemical Carcinogenesis, Institute of Carcinogenesis, Blokhin Cancer Research Center RAMS. E-mail: mrkir@rambler
E.E. Antoshina - Ph.D. (Med.), Senior Researcher, Department of Chemical Carcinogenesis, Institute of Carcinogenesis, Blokhin Cancer Research Center RAMS. E-mail: canceragent@gmail.com
T.G. Gorkova - Researcher, Department of Chemical Carcinogenesis, Institute of Carcinogenesis, Blokhin Cancer Research Center RAMS. E-mail: canceragent@gmail.com
L.S. Trukhanova - Ph.D., Senior Researcher, Department of Chemical Carcinogenesis, Institute of Carcinogenesis, Blokhin Cancer Research Center RAMS. E-mail: canceragent@gmail.com
G.A. Belitsky - Dr. Sc. (Med.), Leading Researcher, Department of Chemical Carcinogenesis, Institute of Carcinogenesis, Blokhin Cancer Research Center RAMS. E-mail: belitsga@gmail.com
M.G. Yakubovskaya - Dr. Sc. (Med.), Head of Department of Chemical Carcinogenesis, Institute of Carcinogenesis, Blokhin Cancer Research Center RAMS. E-mail: mgyakubovskaya@mail.ru
Abstract:
Modern methods of Benign Prostate Hyperplasia (BPH) induction in rats are based on two main approaches: by an increase of testosterone or prolactin levels in blood. First of them is realized by testosterone injections or by subcutaneous solid implants that serves as androgen repository. The second one stimulates prolactin overproduction in pituitary gland by sulpiride, a selective antagonist at dopamine D2 receptors and usually used as a neuroleptic drug. Comparison of morphological, functional, histological, cytological and molecular-biological peculiarities of human and rat prostate was performed to evaluate adequacy and goodness of different BPH models. According to this analysis, most parameters of human prostate hyperplasia are reproduced in the lateral lobe prostate of rat treated by sulpiride.
Pages: 55-64
References
  1. Orsted D.D., Bojesen S.E. The link between benign prostatic hyperplasia and prostate cancer // Nat. Rev. Urol. 2013. V. 10. № 1. P. 49-54.
  2. Matveev B.P., Buxarkin B.V., Matveev V.B. Rak predstatel'noj zhelezy'. M. 1999.
  3. Loran O.B., Pushkar' D.Ju., Rasner P.I. Dobrokachestvennaya giperplaziya predstatel'noj zhelezy': princzipy' medikamentoznoj terapii // Consilium medicum. 2001. V. 7. P. 312-316.
  4. Lepor H. The role of gonadotropin-releasing hormone antagonists for the treatment of benign prostatic hyperplasia // Rev. Urol. 2006. V. 8. № 4. P. 183-189
  5. Azzouni F., Godoy A., Li Y., Mohler J. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases // Adv. Urol. 2012. V. 2012. № 530121. P. 1-18.
  6. Patologoanatomicheskaya diagnostika opuxolej cheloveka / pod red. N.A. Kraevskogo, A.V. Smol'yannikova, D.S. Sarkisova. M. Mediczina. 1993.
  7. Ito N., Shirai T. Tumours of the accessory male sex organs. In: Pathology of tumours in laboratory animals. V. 1. Tumours of the rat. (Ed. V. Turusov, U. Mohr) IARC Sci. Publication, Lyon. 1990. V. 99. P. 421-444
  8. Price D. Comparative aspects of development and structure in the prostate // Natl. Cancer Inst. Monogr. 1963. V. 12. P. 351-369.
  9. Nevalainen M.T., Valve E.M., Ingleton P.M. et al. Prolactin and prolactin receptors are expressed and functioning in human prostate // J. Clin. Invest. 1997. V. 99. № 4. P. 618-27.
  10. Crepin A., Bidaux G., Vanden-Abeele F. et al. Prolactin stimulates prostate cell proliferation by increasing endoplasmic reticulum content due to SERCA 2b over-expression // Biochem. J. 2007. V. 401. № 1. P. 49-55.
  11. Titus M.A., Zeithaml B., Kantor B. et al. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer // PLoS One. 2012. V. 7. № 1: e30192.
  12. de Ronde W., Hofman A., Pols H.A., de Jong F.H. A direct approach to the estimation of the origin of oestrogens and androgens in elderly men by comparison with hormone levels in postmenopausal women // Eur. J. Endocrinol. 2005. V. 152. № 2. P. 261-8.
  13. Iehle C., Radvanyi F., Gil Diez de Medina S. et al. Differences in steroid 5alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue // J. Steroid Biochem. Mol. Biol. 1999. V. 68. № 5-6. P. 189-9.
  14. Sanchez P., Torres J.M., Castro B. et al. Expression of steroid 5α-reductase isozymes in prostate of adult rats after environmental stress // FEBS J. 2013. V. 280. № 1. P. 93-101
  15. Saartok T., Dahlberg E., Gustafsson J.A. Relative binding affinity of anabolic-androgenic steroids: comparison of the binding to the androgen receptors in skeletal muscle and in prostate, as well as to sex hormone-binding globulin // Endocrinology. 1984. V. 114. № 6. P. 2100-6.
  16. Degtyar' V.G., Kushlinskij N.E. Speczificheskie svojstva reczeptorov androgenov cheloveka // Sibirskij onkologicheskij zhurnal. 2005. T. 3. № 15. P. 58-67.
  17. Snoek R., Cheng H., Margiotti K. et al. In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors // Clin. Cancer. Res. 2009. V. 15. P. 39-47.
  18. Prins G.S., Birch L., Greene G.L. Androgen receptor localization in different cell types of the adult rat prostate // Endocrinology. 1991. V. 129. № 6. P. 3187-99.
  19. Cunha G.R., Hayward S.W., Wang Y.Z., Ricke W.A. Role of the stromal microenvironment in carcinogenesis of the prostate // Int. J. Cancer. 2003. V. 107. № 1. P. 1-10.
  20. Lai K.P., Yamashita S., Huang C.-K. et al. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines/chemokines // EMBO Mol. Med. 2012. V. 4. P. 791-807.
  21. Farnsworth W.E. Prolactin effect on the permeability of human benign hyperplastic prostate to testosterone // Prostate. 1988. V. 12. P. 221-229.
  22. Prins G.S. Prolactin influence of cytosol and nuclear androgen receptors in the ventral, dorsal and lateral lobes of the rat prostate // Endocrinology. 1987. V. 120. P. 1457-1464.
  23. Leav I., Merk F.B., Lee K.F. et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions // Am. J. Pathol. 1999. V. 154. № 3. P. 863-870.
  24. Nevalainen M.T., Valve E.M., Ahonen T. et al. Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture // FASEB J. 1997. V. 11. № 14. P. 1297-1307.
  25. Wennbo H., Kindblom J., Isaksson O.G.P., Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland // Endocrinology. 1997. V. 138. P. 4410-4415.
  26. Sánchez P., Torres J.M., Vílchez P. et al. Effects of sulpiride on mRNA levels of steroid 5alpha-reductase isozymes in prostate of adult rats // IUBMB Life. 2008. V. 60. № 1. P. 68-72.
  27. Nevalainen M.T., Valve E.M., Ingleton P.M. et al. Prolactin and prolactin receptors are expressed and functioning in human prostate // J. Clin. Invest. 1997. V. 99. № 4. P. 618-627.
  28. Van Coppenolle F., Skryma R., Ouadid-Ahidouch H. et al. Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation // Biochem. J. 2004. V. 377. № 3. P. 569-578.
  29. Bole-Feysot C., Goffin V., Edery M. et al. A. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice // Endocrinol. Rev. 1998. V. 19. P. 225-268.
  30. Nankin H.R., Calkins J.H., Hammond G.L. et al. Serum FSH, LH and prolactin in normal males and patients with prostatic diseases // Clin. Endocrinol. 1977. V. 7. P. 129-135.
  31. van der Sluis T.M., Vis A.N., van Moorselaar R.J. et al. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer // BJU Int. 2012. V. 109. № 2. P. 176-182.
  32. van der Sluis T.M., Meuleman E.J., van Moorselaar R.J. et al. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer // BJU Int. 2012. V. 109. № 2. P. 183-188.
  33. Borovskaya T.G., Fomina T.I., Durnev A.D. i soavt. Metodicheskix rekomendacziyax po doklinicheskomu izucheniyu prostatotropnoj aktivnosti lekarstvenny'x sredstv / V kn. Rukovodstvo po provedeniyu doklinicheskix issledovanij lekarstvenny'x sredstv. M.: Grif i K. 2012. Gl. 46. C. 727-738.
  34. Kudryavczev Ju.V., Sivkov A.V. Morfologicheskie izmeneniya v tkani predstatel'noj zhelezy' pri dobrokachestvennoj giperplazii // E'ksperimental'naya i klinicheskaya urologiya. 2010. T. 2. № 1. S. 18-22.
  35. Banerjee P.P., Banerjee S., Dorsey R. et al. Age- and Lobe-Specific Responses of the Brown Norway Rat Prostate to Androgen // Biol. Reprod. 1994. V. 51. P. 675-684.
  36. Prins G.S. Differential regulation of androgen receptors in the separate rat prostate lobes: androgen independent expression in the lateral lobe // J. Steroid. Biochem. 1989. V. 33. № 3. P. 319-326.
  37. Sluczanowska-Glabowska S., Laszczynska M., Wylot M. et al. Morphological and immunohistochemical comparison of three rat prostate lobes (lateral, dorsal and ventral) in experimental hyperprolactinemia // Folia. Histochem. Cytobiol. 2010. V. 48. № 3. R. 447-454.
  38. Van Coppenolle F., Slomianny C., Carpentier F. et al. Effect of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence // Am. J. Physio. Endocrinol. Metab. 2001. V. 280. P. 120-129.
  39. Yan J., Brown T.R. Cell proliferation and expression of cell cycle regulatory proteins that control the G1/S transition are age dependent and lobe specific in the Brown Norway rat model of prostatic hyperplasia // Endocrinology. 2008. V. 149. № 1. P. 193-207.
  40. Aumuller G. Morphologic and regulatory aspects of prostatic function // Anat. Embryol. 1989. V. 179. P. 519-531.
  41. Banerjee S., Banerjee P.P., Brown T.R. Castration-induced apoptotic cell death in the Brown Norway rat prostate decreases as a function of age // Endocrinology. 2000. V. 141. № 2. P. 821-832.